NCT03761914 2024-11-19
Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers
Sellas Life Sciences Group
Phase 1/2 Completed
Sellas Life Sciences Group
National Institutes of Health Clinical Center (CC)
National Cancer Institute (NCI)
Immatics Biotechnologies GmbH